

## Special Issue

# p53 Family in Cancer: How Close Are We to the Clinic? (2nd Edition)

### Message from the Guest Editors

This Special Issue is a continuation of our previous one, entitled "p53 Family in Cancer: How Close Are We to the Clinic?". With this Special Issue, we are pleased to invite you to submit your work describing recent advances in this field, which may pave the way for more effective therapeutic strategies against cancer. In this issue, original research articles and reviews are welcome. The research areas may include (but are not limited to) basic and more (pre)clinical aspects of the function, biology, and pharmacology of the p53 family. We look forward to receiving your contributions.

### Guest Editors

Dr. Lucília Saraiva

LAQV/REQUIMTE, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 228, 4050-313 Porto, Portugal

Dr. Marco M. Candeias

1. Molecular and RNA Cancer Unit, Kyoto University Graduate School of Medicine, Building E Rm 115, Yoshida Konoemachi, Sakyo-ku, Kyoto 606-8501, Japan

2. Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Avenida Padre Cruz, 1649-016 Lisboa, Portugal

3. BiolSI—BioSystems & Integrative Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### Deadline for manuscript submissions

20 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/236342](https://mdpi.com/si/236342)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)